Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07658924 Benvitimod Mycosis Fungoides Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658924, evaluating Benvitimod in Mycosis Fungoides: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07659795 Cetuximab KRAS G12D mutation Colorectal cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659795, evaluating Cetuximab in KRAS G12D mutation Colorectal cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
ChiCTR2600126996 Sintilimab Metastatic Gastrointestinal Stromal Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600126996, evaluating Sintilimab in Metastatic Gastrointestinal Stromal Tumor: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Axatilimab-csfr Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Axatilimab-csfr: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661602 Folic Acid Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661602, evaluating Folic Acid in Anemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07659379 Gotistobart Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659379, evaluating Gotistobart in Advanced Malignant Solid Neoplasm: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Stapokibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Stapokibart: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661771 IMRT with Individualized Primary Clinical Target Volume Based on Margin Expansion Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661771, evaluating IMRT with Individualized Primary Clinical Target Volume Based on Margin Expansion in Nasopharyngeal Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Ivarmacitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ivarmacitinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661927 Removing Endocrine Therapy Early Stage Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661927, evaluating Removing Endocrine Therapy in Early Stage Breast Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07660796 Amlodipine/chlorthalidone/losartan Essential Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07660796, evaluating Amlodipine/chlorthalidone/losartan in Essential Hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Rabeprazole Sodium/Sodium Bicarbonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rabeprazole Sodium/Sodium Bicarbonate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.